id	sid	tid	token	lemma	pos
dpc-2229	1	1	dermatology	dermatology	NOUN
dpc-2229	1	2	:	:	PUNCT
dpc-2229	1	3	practical	practical	ADJ
dpc-2229	1	4	and	and	CCONJ
dpc-2229	1	5	conceptual	conceptual	ADJ
dpc-2229	1	6	research	research	NOUN
dpc-2229	1	7	letter	letter	NOUN
dpc-2229	2	1	|	|	ADV
dpc-2229	2	2	dermatol	dermatol	ADJ
dpc-2229	2	3	pract	pract	NOUN
dpc-2229	2	4	concept	concept	NOUN
dpc-2229	2	5	.	.	PUNCT
dpc-2229	3	1	2022;12(4):e2022184	2022;12(4):e2022184	NUM
dpc-2229	3	2	1	1	NUM
dpc-2229	3	3	dupilumab	dupilumab	NOUN
dpc-2229	3	4	-	-	PUNCT
dpc-2229	3	5	associated	associate	VERB
dpc-2229	3	6	facial	facial	ADJ
dpc-2229	3	7	erythema	erythema	NOUN
dpc-2229	3	8	successfully	successfully	ADV
dpc-2229	3	9	treated	treat	VERB
dpc-2229	3	10	with	with	ADP
dpc-2229	3	11	oral	oral	ADJ
dpc-2229	3	12	ivermectin	ivermectin	NOUN
dpc-2229	3	13	javier	javier	PROPN
dpc-2229	3	14	gil	gil	PROPN
dpc-2229	3	15	liane1	liane1	PROPN
dpc-2229	3	16	,	,	PUNCT
dpc-2229	3	17	daniel	daniel	PROPN
dpc-2229	3	18	morgado	morgado	PROPN
dpc-2229	3	19	-	-	PUNCT
dpc-2229	3	20	carrasco1	carrasco1	ADJ
dpc-2229	3	21	1	1	NUM
dpc-2229	3	22	department	department	NOUN
dpc-2229	3	23	of	of	ADP
dpc-2229	3	24	dermatology	dermatology	NOUN
dpc-2229	3	25	,	,	PUNCT
dpc-2229	3	26	university	university	PROPN
dpc-2229	3	27	of	of	ADP
dpc-2229	3	28	barcelona	barcelona	PROPN
dpc-2229	3	29	,	,	PUNCT
dpc-2229	3	30	hospital	hospital	PROPN
dpc-2229	3	31	clinic	clinic	PROPN
dpc-2229	3	32	barcelona	barcelona	PROPN
dpc-2229	3	33	,	,	PUNCT
dpc-2229	3	34	spain	spain	PROPN
dpc-2229	3	35	key	key	ADJ
dpc-2229	3	36	words	word	NOUN
dpc-2229	3	37	:	:	PUNCT
dpc-2229	3	38	dupilumab	dupilumab	NOUN
dpc-2229	3	39	,	,	PUNCT
dpc-2229	3	40	facial	facial	ADJ
dpc-2229	3	41	dermatitis	dermatitis	NOUN
dpc-2229	3	42	,	,	PUNCT
dpc-2229	3	43	atopic	atopic	NOUN
dpc-2229	3	44	dermatitis	dermatitis	NOUN
dpc-2229	3	45	,	,	PUNCT
dpc-2229	3	46	ivermectin	ivermectin	NOUN
dpc-2229	3	47	citation	citation	NOUN
dpc-2229	3	48	:	:	PUNCT
dpc-2229	3	49	gil	gil	PROPN
dpc-2229	3	50	-	-	PUNCT
dpc-2229	3	51	lianes	lianes	PROPN
dpc-2229	3	52	j	j	PROPN
dpc-2229	3	53	,	,	PUNCT
dpc-2229	3	54	morgado	morgado	PROPN
dpc-2229	3	55	-	-	PUNCT
dpc-2229	3	56	carrasco	carrasco	PROPN
dpc-2229	3	57	d.	d.	PROPN
dpc-2229	3	58	dupilumab	dupilumab	PROPN
dpc-2229	3	59	-	-	PUNCT
dpc-2229	3	60	associated	associate	VERB
dpc-2229	3	61	facial	facial	ADJ
dpc-2229	3	62	erythema	erythema	NOUN
dpc-2229	3	63	successfully	successfully	ADV
dpc-2229	3	64	treated	treat	VERB
dpc-2229	3	65	with	with	ADP
dpc-2229	3	66	oral	oral	ADJ
dpc-2229	3	67	ivermectin	ivermectin	NOUN
dpc-2229	3	68	.	.	PUNCT
dpc-2229	4	1	dermatol	dermatol	NOUN
dpc-2229	4	2	pract	pract	PROPN
dpc-2229	4	3	concept	concept	NOUN
dpc-2229	4	4	.	.	PUNCT
dpc-2229	5	1	2022;12(4):e2022184	2022;12(4):e2022184	X
dpc-2229	5	2	.	.	PUNCT
dpc-2229	5	3	doi	doi	NOUN
dpc-2229	5	4	:	:	PUNCT
dpc-2229	5	5	https://doi.org/10.5826/dpc.1204a184	https://doi.org/10.5826/dpc.1204a184	VERB
dpc-2229	5	6	accepted	accept	VERB
dpc-2229	5	7	:	:	PUNCT
dpc-2229	5	8	january	january	PROPN
dpc-2229	5	9	19	19	NUM
dpc-2229	5	10	,	,	PUNCT
dpc-2229	5	11	2022	2022	NUM
dpc-2229	5	12	;	;	PUNCT
dpc-2229	5	13	published	publish	VERB
dpc-2229	5	14	:	:	PUNCT
dpc-2229	5	15	october	october	PROPN
dpc-2229	5	16	2022	2022	NUM
dpc-2229	6	1	copyright	copyright	NOUN
dpc-2229	6	2	:	:	PUNCT
dpc-2229	6	3	©	©	PROPN
dpc-2229	6	4	2022	2022	NUM
dpc-2229	6	5	gil	gil	PROPN
dpc-2229	6	6	-	-	PUNCT
dpc-2229	6	7	lianes	liane	NOUN
dpc-2229	6	8	et	et	PROPN
dpc-2229	6	9	al	al	PROPN
dpc-2229	6	10	.	.	PUNCT
dpc-2229	7	1	this	this	PRON
dpc-2229	7	2	is	be	AUX
dpc-2229	7	3	an	an	DET
dpc-2229	7	4	open	open	ADJ
dpc-2229	7	5	-	-	PUNCT
dpc-2229	7	6	access	access	NOUN
dpc-2229	7	7	article	article	NOUN
dpc-2229	7	8	distributed	distribute	VERB
dpc-2229	7	9	under	under	ADP
dpc-2229	7	10	the	the	DET
dpc-2229	7	11	terms	term	NOUN
dpc-2229	7	12	of	of	ADP
dpc-2229	7	13	the	the	DET
dpc-2229	7	14	creative	creative	ADJ
dpc-2229	7	15	commons	common	NOUN
dpc-2229	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2229	7	17	license	license	NOUN
dpc-2229	7	18	(	(	PUNCT
dpc-2229	7	19	by	by	ADP
dpc-2229	7	20	-	-	PUNCT
dpc-2229	7	21	nc-4.0	nc-4.0	NOUN
dpc-2229	7	22	)	)	PUNCT
dpc-2229	7	23	,	,	PUNCT
dpc-2229	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2229	7	25	,	,	PUNCT
dpc-2229	7	26	which	which	PRON
dpc-2229	7	27	permits	permit	VERB
dpc-2229	7	28	unrestricted	unrestricted	ADJ
dpc-2229	7	29	noncommercial	noncommercial	ADJ
dpc-2229	7	30	use	use	NOUN
dpc-2229	7	31	,	,	PUNCT
dpc-2229	7	32	distribution	distribution	NOUN
dpc-2229	7	33	,	,	PUNCT
dpc-2229	7	34	and	and	CCONJ
dpc-2229	7	35	reproduction	reproduction	NOUN
dpc-2229	7	36	in	in	ADP
dpc-2229	7	37	any	any	DET
dpc-2229	7	38	medium	medium	NOUN
dpc-2229	7	39	,	,	PUNCT
dpc-2229	7	40	provided	provide	VERB
dpc-2229	7	41	the	the	DET
dpc-2229	7	42	original	original	ADJ
dpc-2229	7	43	authors	author	NOUN
dpc-2229	7	44	and	and	CCONJ
dpc-2229	7	45	source	source	NOUN
dpc-2229	7	46	are	be	AUX
dpc-2229	7	47	credited	credit	VERB
dpc-2229	7	48	.	.	PUNCT
dpc-2229	8	1	funding	funding	NOUN
dpc-2229	8	2	:	:	PUNCT
dpc-2229	8	3	none	none	NOUN
dpc-2229	8	4	.	.	PUNCT
dpc-2229	9	1	competing	compete	VERB
dpc-2229	9	2	interests	interest	NOUN
dpc-2229	9	3	:	:	PUNCT
dpc-2229	9	4	none	none	NOUN
dpc-2229	9	5	.	.	PUNCT
dpc-2229	10	1	authorship	authorship	NOUN
dpc-2229	10	2	:	:	PUNCT
dpc-2229	10	3	all	all	DET
dpc-2229	10	4	authors	author	NOUN
dpc-2229	10	5	have	have	AUX
dpc-2229	10	6	contributed	contribute	VERB
dpc-2229	10	7	significantly	significantly	ADV
dpc-2229	10	8	to	to	ADP
dpc-2229	10	9	this	this	DET
dpc-2229	10	10	publication	publication	NOUN
dpc-2229	10	11	.	.	PUNCT
dpc-2229	11	1	corresponding	correspond	VERB
dpc-2229	11	2	author	author	NOUN
dpc-2229	11	3	:	:	PUNCT
dpc-2229	11	4	daniel	daniel	PROPN
dpc-2229	11	5	morgado	morgado	PROPN
dpc-2229	11	6	-	-	PUNCT
dpc-2229	11	7	carrasco	carrasco	PROPN
dpc-2229	11	8	,	,	PUNCT
dpc-2229	11	9	md	md	PROPN
dpc-2229	11	10	,	,	PUNCT
dpc-2229	11	11	dermatology	dermatology	NOUN
dpc-2229	11	12	department	department	NOUN
dpc-2229	11	13	,	,	PUNCT
dpc-2229	11	14	hospital	hospital	NOUN
dpc-2229	11	15	clínic	clínic	PROPN
dpc-2229	11	16	de	de	PROPN
dpc-2229	11	17	barcelona	barcelona	PROPN
dpc-2229	11	18	,	,	PUNCT
dpc-2229	11	19	barcelona	barcelona	PROPN
dpc-2229	11	20	.	.	PROPN
dpc-2229	11	21	c/	c/	PROPN
dpc-2229	12	1	villarroel	villarroel	PROPN
dpc-2229	12	2	,	,	PUNCT
dpc-2229	12	3	170	170	NUM
dpc-2229	12	4	,	,	PUNCT
dpc-2229	12	5	08036	08036	NUM
dpc-2229	12	6	barcelona	barcelona	PROPN
dpc-2229	12	7	,	,	PUNCT
dpc-2229	12	8	spain	spain	PROPN
dpc-2229	12	9	.	.	PUNCT
dpc-2229	13	1	phone	phone	NOUN
dpc-2229	13	2	:	:	PUNCT
dpc-2229	13	3	(	(	PUNCT
dpc-2229	13	4	+34	+34	ADJ
dpc-2229	13	5	)	)	PUNCT
dpc-2229	13	6	93	93	NUM
dpc-2229	13	7	227	227	NUM
dpc-2229	13	8	54	54	NUM
dpc-2229	13	9	00	00	NUM
dpc-2229	13	10	,	,	PUNCT
dpc-2229	13	11	fax	fax	NOUN
dpc-2229	13	12	:	:	PUNCT
dpc-2229	13	13	(	(	PUNCT
dpc-2229	13	14	+34	+34	ADJ
dpc-2229	13	15	)	)	PUNCT
dpc-2229	13	16	932275438	932275438	NUM
dpc-2229	13	17	,	,	PUNCT
dpc-2229	13	18	e	e	NOUN
dpc-2229	13	19	-	-	NOUN
dpc-2229	13	20	mail	mail	NOUN
dpc-2229	13	21	:	:	PUNCT
dpc-2229	13	22	morgadodaniel8@gmail.com	morgadodaniel8@gmail.com	X
dpc-2229	13	23	introduction	introduction	NOUN
dpc-2229	13	24	dupilumab	dupilumab	NOUN
dpc-2229	13	25	,	,	PUNCT
dpc-2229	13	26	a	a	DET
dpc-2229	13	27	monoclonal	monoclonal	NOUN
dpc-2229	13	28	antibody	antibody	NOUN
dpc-2229	13	29	which	which	PRON
dpc-2229	13	30	inhibits	inhibit	VERB
dpc-2229	13	31	il-4	il-4	PRON
dpc-2229	13	32	and	and	CCONJ
dpc-2229	13	33	il-13	il-13	ADV
dpc-2229	13	34	signaling	signal	VERB
dpc-2229	13	35	,	,	PUNCT
dpc-2229	13	36	has	have	AUX
dpc-2229	13	37	revolutionized	revolutionize	VERB
dpc-2229	13	38	atopic	atopic	NOUN
dpc-2229	13	39	dermatitis	dermatitis	NOUN
dpc-2229	13	40	(	(	PUNCT
dpc-2229	13	41	ad	ad	NOUN
dpc-2229	13	42	)	)	PUNCT
dpc-2229	13	43	treatment	treatment	NOUN
dpc-2229	13	44	.	.	PUNCT
dpc-2229	14	1	dupilumab	dupilumab	NOUN
dpc-2229	14	2	-	-	PUNCT
dpc-2229	14	3	associated	associate	VERB
dpc-2229	14	4	facial	facial	ADJ
dpc-2229	14	5	erythema	erythema	NOUN
dpc-2229	14	6	(	(	PUNCT
dpc-2229	14	7	dfe	dfe	PROPN
dpc-2229	14	8	)	)	PUNCT
dpc-2229	14	9	has	have	AUX
dpc-2229	14	10	been	be	AUX
dpc-2229	14	11	described	describe	VERB
dpc-2229	14	12	in	in	ADP
dpc-2229	14	13	10	10	NUM
dpc-2229	14	14	%	%	NOUN
dpc-2229	14	15	of	of	ADP
dpc-2229	14	16	patients	patient	NOUN
dpc-2229	14	17	and	and	CCONJ
dpc-2229	14	18	can	can	AUX
dpc-2229	14	19	lead	lead	VERB
dpc-2229	14	20	to	to	ADP
dpc-2229	14	21	dupilumab	dupilumab	NOUN
dpc-2229	14	22	discontinuation	discontinuation	NOUN
dpc-2229	15	1	[	[	X
dpc-2229	15	2	1	1	NUM
dpc-2229	15	3	]	]	PUNCT
dpc-2229	15	4	.	.	PUNCT
dpc-2229	16	1	etiology	etiology	NOUN
dpc-2229	16	2	remains	remain	VERB
dpc-2229	16	3	unclear	unclear	ADJ
dpc-2229	16	4	and	and	CCONJ
dpc-2229	16	5	treatment	treatment	NOUN
dpc-2229	16	6	is	be	AUX
dpc-2229	16	7	challenging	challenge	VERB
dpc-2229	16	8	[	[	PUNCT
dpc-2229	16	9	1	1	NUM
dpc-2229	16	10	-	-	SYM
dpc-2229	16	11	3	3	NUM
dpc-2229	16	12	]	]	PUNCT
dpc-2229	16	13	.	.	PUNCT
dpc-2229	17	1	here	here	ADV
dpc-2229	17	2	we	we	PRON
dpc-2229	17	3	present	present	VERB
dpc-2229	17	4	a	a	DET
dpc-2229	17	5	patient	patient	NOUN
dpc-2229	17	6	with	with	ADP
dpc-2229	17	7	dfe	dfe	PROPN
dpc-2229	17	8	successfully	successfully	ADV
dpc-2229	17	9	treated	treat	VERB
dpc-2229	17	10	with	with	ADP
dpc-2229	17	11	oral	oral	ADJ
dpc-2229	17	12	ivermectin	ivermectin	NOUN
dpc-2229	17	13	.	.	PUNCT
dpc-2229	18	1	case	case	NOUN
dpc-2229	18	2	presentation	presentation	NOUN
dpc-2229	18	3	a	a	DET
dpc-2229	18	4	20	20	NUM
dpc-2229	18	5	-	-	PUNCT
dpc-2229	18	6	year	year	NOUN
dpc-2229	18	7	-	-	PUNCT
dpc-2229	18	8	old	old	ADJ
dpc-2229	18	9	woman	woman	NOUN
dpc-2229	18	10	with	with	ADP
dpc-2229	18	11	severe	severe	ADJ
dpc-2229	18	12	ad	ad	NOUN
dpc-2229	18	13	,	,	PUNCT
dpc-2229	18	14	refractory	refractory	NOUN
dpc-2229	18	15	to	to	PART
dpc-2229	18	16	cyclosporine	cyclosporine	VERB
dpc-2229	18	17	,	,	PUNCT
dpc-2229	18	18	started	start	VERB
dpc-2229	18	19	dupilumab	dupilumab	NOUN
dpc-2229	18	20	.	.	PUNCT
dpc-2229	19	1	after	after	ADP
dpc-2229	19	2	6	6	NUM
dpc-2229	19	3	weeks	week	NOUN
dpc-2229	19	4	,	,	PUNCT
dpc-2229	19	5	although	although	SCONJ
dpc-2229	19	6	ad	ad	NOUN
dpc-2229	19	7	lesions	lesion	NOUN
dpc-2229	19	8	had	have	AUX
dpc-2229	19	9	resolved	resolve	VERB
dpc-2229	19	10	,	,	PUNCT
dpc-2229	19	11	she	she	PRON
dpc-2229	19	12	manifested	manifest	VERB
dpc-2229	19	13	itching	itching	NOUN
dpc-2229	19	14	and	and	CCONJ
dpc-2229	19	15	facial	facial	ADJ
dpc-2229	19	16	erythema	erythema	NOUN
dpc-2229	19	17	which	which	PRON
dpc-2229	19	18	were	be	AUX
dpc-2229	19	19	not	not	PART
dpc-2229	19	20	previously	previously	ADV
dpc-2229	19	21	present	present	ADJ
dpc-2229	19	22	.	.	PUNCT
dpc-2229	20	1	on	on	ADP
dpc-2229	20	2	physical	physical	ADJ
dpc-2229	20	3	examination	examination	NOUN
dpc-2229	20	4	,	,	PUNCT
dpc-2229	20	5	scaly	scaly	NOUN
dpc-2229	20	6	ill	ill	ADV
dpc-2229	20	7	-	-	PUNCT
dpc-2229	20	8	defined	define	VERB
dpc-2229	20	9	erythematous	erythematous	ADJ
dpc-2229	20	10	plaques	plaque	NOUN
dpc-2229	20	11	were	be	AUX
dpc-2229	20	12	observed	observe	VERB
dpc-2229	20	13	on	on	ADP
dpc-2229	20	14	the	the	DET
dpc-2229	20	15	forehead	forehead	NOUN
dpc-2229	20	16	and	and	CCONJ
dpc-2229	20	17	cheeks	cheek	NOUN
dpc-2229	20	18	.	.	PUNCT
dpc-2229	21	1	dermoscopy	dermoscopy	NOUN
dpc-2229	21	2	showed	show	VERB
dpc-2229	21	3	small	small	ADJ
dpc-2229	21	4	pustules	pustule	NOUN
dpc-2229	21	5	(	(	PUNCT
dpc-2229	21	6	figure	figure	NOUN
dpc-2229	21	7	1	1	NUM
dpc-2229	21	8	a	a	PRON
dpc-2229	21	9	and	and	CCONJ
dpc-2229	21	10	b	b	NOUN
dpc-2229	21	11	)	)	PUNCT
dpc-2229	21	12	.	.	PUNCT
dpc-2229	22	1	dfe	dfe	PROPN
dpc-2229	22	2	was	be	AUX
dpc-2229	22	3	diagnosed	diagnose	VERB
dpc-2229	22	4	.	.	PUNCT
dpc-2229	23	1	no	no	DET
dpc-2229	23	2	patch	patch	NOUN
dpc-2229	23	3	tests	test	NOUN
dpc-2229	23	4	were	be	AUX
dpc-2229	23	5	performed	perform	VERB
dpc-2229	23	6	.	.	PUNCT
dpc-2229	24	1	there	there	PRON
dpc-2229	24	2	was	be	VERB
dpc-2229	24	3	no	no	DET
dpc-2229	24	4	response	response	NOUN
dpc-2229	24	5	to	to	ADP
dpc-2229	24	6	topical	topical	ADJ
dpc-2229	24	7	corticosteroids	corticosteroid	NOUN
dpc-2229	24	8	or	or	CCONJ
dpc-2229	24	9	tacrolimus	tacrolimus	NOUN
dpc-2229	24	10	with	with	ADP
dpc-2229	24	11	local	local	ADJ
dpc-2229	24	12	adverse	adverse	ADJ
dpc-2229	24	13	effects	effect	NOUN
dpc-2229	24	14	(	(	PUNCT
dpc-2229	24	15	ae	ae	PROPN
dpc-2229	24	16	)	)	PUNCT
dpc-2229	24	17	,	,	PUNCT
dpc-2229	24	18	nor	nor	CCONJ
dpc-2229	24	19	to	to	ADP
dpc-2229	24	20	oral	oral	ADJ
dpc-2229	24	21	itraconazole	itraconazole	NOUN
dpc-2229	24	22	and	and	CCONJ
dpc-2229	24	23	topical	topical	ADJ
dpc-2229	24	24	ketoconazole	ketoconazole	NOUN
dpc-2229	24	25	.	.	PUNCT
dpc-2229	25	1	since	since	SCONJ
dpc-2229	25	2	small	small	ADJ
dpc-2229	25	3	pustules	pustule	NOUN
dpc-2229	25	4	were	be	AUX
dpc-2229	25	5	present	present	ADJ
dpc-2229	25	6	on	on	ADP
dpc-2229	25	7	dermoscopy	dermoscopy	NOUN
dpc-2229	25	8	,	,	PUNCT
dpc-2229	25	9	dupilumab	dupilumab	NOUN
dpc-2229	25	10	-	-	PUNCT
dpc-2229	25	11	associated	associate	VERB
dpc-2229	25	12	rosacea	rosacea	NOUN
dpc-2229	25	13	was	be	AUX
dpc-2229	25	14	suspected	suspect	VERB
dpc-2229	25	15	.	.	PUNCT
dpc-2229	26	1	to	to	PART
dpc-2229	26	2	avoid	avoid	VERB
dpc-2229	26	3	local	local	ADJ
dpc-2229	26	4	ae	ae	PROPN
dpc-2229	26	5	,	,	PUNCT
dpc-2229	26	6	a	a	DET
dpc-2229	26	7	single	single	ADJ
dpc-2229	26	8	dose	dose	NOUN
dpc-2229	26	9	of	of	ADP
dpc-2229	26	10	oral	oral	ADJ
dpc-2229	26	11	ivermectin	ivermectin	NOUN
dpc-2229	26	12	200	200	NUM
dpc-2229	26	13	mcg	mcg	NOUN
dpc-2229	26	14	/	/	SYM
dpc-2229	26	15	kg	kg	PROPN
dpc-2229	26	16	(	(	PUNCT
dpc-2229	26	17	12	12	NUM
dpc-2229	26	18	mg	mg	NOUN
dpc-2229	26	19	)	)	PUNCT
dpc-2229	26	20	was	be	AUX
dpc-2229	26	21	prescribed	prescribe	VERB
dpc-2229	26	22	.	.	PUNCT
dpc-2229	27	1	the	the	DET
dpc-2229	27	2	patient	patient	NOUN
dpc-2229	27	3	presented	present	VERB
dpc-2229	27	4	a	a	DET
dpc-2229	27	5	complete	complete	ADJ
dpc-2229	27	6	resolution	resolution	NOUN
dpc-2229	27	7	of	of	ADP
dpc-2229	27	8	facial	facial	ADJ
dpc-2229	27	9	erythema	erythema	NOUN
dpc-2229	27	10	in	in	ADP
dpc-2229	27	11	3	3	NUM
dpc-2229	27	12	weeks	week	NOUN
dpc-2229	27	13	,	,	PUNCT
dpc-2229	27	14	which	which	PRON
dpc-2229	27	15	has	have	AUX
dpc-2229	27	16	been	be	AUX
dpc-2229	27	17	maintained	maintain	VERB
dpc-2229	27	18	after	after	ADP
dpc-2229	27	19	14	14	NUM
dpc-2229	27	20	months	month	NOUN
dpc-2229	27	21	of	of	ADP
dpc-2229	27	22	follow	follow	NOUN
dpc-2229	27	23	-	-	PUNCT
dpc-2229	27	24	up	up	NOUN
dpc-2229	27	25	(	(	PUNCT
dpc-2229	27	26	figure	figure	NOUN
dpc-2229	27	27	2	2	NUM
dpc-2229	27	28	)	)	PUNCT
dpc-2229	27	29	.	.	PUNCT
dpc-2229	28	1	conclusions	conclusion	NOUN
dpc-2229	28	2	face	face	VERB
dpc-2229	28	3	and	and	CCONJ
dpc-2229	28	4	neck	neck	NOUN
dpc-2229	28	5	dermatitis	dermatitis	PROPN
dpc-2229	28	6	(	(	PUNCT
dpc-2229	28	7	fnd	fnd	PROPN
dpc-2229	28	8	)	)	PUNCT
dpc-2229	28	9	in	in	ADP
dpc-2229	28	10	atopic	atopic	NOUN
dpc-2229	28	11	dermatitis	dermatitis	NOUN
dpc-2229	28	12	is	be	AUX
dpc-2229	28	13	a	a	DET
dpc-2229	28	14	diagnostic	diagnostic	ADJ
dpc-2229	28	15	challenge	challenge	NOUN
dpc-2229	28	16	in	in	ADP
dpc-2229	28	17	which	which	PRON
dpc-2229	28	18	dupilumab	dupilumab	NOUN
dpc-2229	28	19	adds	add	VERB
dpc-2229	28	20	a	a	DET
dpc-2229	28	21	new	new	ADJ
dpc-2229	28	22	grade	grade	NOUN
dpc-2229	28	23	of	of	ADP
dpc-2229	28	24	complexity	complexity	NOUN
dpc-2229	28	25	[	[	X
dpc-2229	28	26	2	2	NUM
dpc-2229	28	27	]	]	PUNCT
dpc-2229	28	28	.	.	PUNCT
dpc-2229	29	1	in	in	ADP
dpc-2229	29	2	a	a	DET
dpc-2229	29	3	recent	recent	ADJ
dpc-2229	29	4	systematic	systematic	ADJ
dpc-2229	29	5	review	review	NOUN
dpc-2229	29	6	of	of	ADP
dpc-2229	29	7	101	101	NUM
dpc-2229	29	8	patients	patient	NOUN
dpc-2229	29	9	with	with	ADP
dpc-2229	29	10	dfe	dfe	PROPN
dpc-2229	29	11	,	,	PUNCT
dpc-2229	29	12	45	45	NUM
dpc-2229	29	13	%	%	NOUN
dpc-2229	29	14	of	of	ADP
dpc-2229	29	15	patients	patient	NOUN
dpc-2229	29	16	reported	report	VERB
dpc-2229	29	17	different	different	ADJ
dpc-2229	29	18	cutaneous	cutaneous	ADJ
dpc-2229	29	19	symptoms	symptom	NOUN
dpc-2229	29	20	from	from	ADP
dpc-2229	29	21	preexisting	preexist	VERB
dpc-2229	29	22	atopic	atopic	NOUN
dpc-2229	29	23	dermatitis	dermatitis	NOUN
dpc-2229	29	24	[	[	X
dpc-2229	29	25	3	3	NUM
dpc-2229	29	26	]	]	PUNCT
dpc-2229	29	27	.	.	PUNCT
dpc-2229	30	1	diverse	diverse	ADJ
dpc-2229	30	2	etiologies	etiology	NOUN
dpc-2229	30	3	for	for	ADP
dpc-2229	30	4	dfe	dfe	PROPN
dpc-2229	30	5	have	have	AUX
dpc-2229	30	6	been	be	AUX
dpc-2229	30	7	proposed	propose	VERB
dpc-2229	30	8	,	,	PUNCT
dpc-2229	30	9	  	  	SPACE
dpc-2229	30	10	including	include	VERB
dpc-2229	30	11	worsening	worsen	VERB
dpc-2229	30	12	of	of	ADP
dpc-2229	30	13	ad	ad	NOUN
dpc-2229	30	14	,	,	PUNCT
dpc-2229	30	15	allergic	allergic	ADJ
dpc-2229	30	16	contact	contact	NOUN
dpc-2229	30	17	dermatitis	dermatitis	NOUN
dpc-2229	30	18	(	(	PUNCT
dpc-2229	30	19	acd	acd	NOUN
dpc-2229	30	20	)	)	PUNCT
dpc-2229	30	21	,	,	PUNCT
dpc-2229	30	22	rosacea	rosacea	NOUN
dpc-2229	30	23	,	,	PUNCT
dpc-2229	30	24	topical	topical	ADJ
dpc-2229	30	25	corticoids	corticoid	NOUN
dpc-2229	30	26	withdrawal	withdrawal	NOUN
dpc-2229	30	27	(	(	PUNCT
dpc-2229	30	28	tcw	tcw	PROPN
dpc-2229	30	29	)	)	PUNCT
dpc-2229	30	30	,	,	PUNCT
dpc-2229	30	31	malassezia	malassezia	NOUN
dpc-2229	30	32	furfur	furfur	NOUN
dpc-2229	30	33	(	(	PUNCT
dpc-2229	30	34	mf	mf	NOUN
dpc-2229	30	35	)	)	PUNCT
dpc-2229	30	36	hypersensitivity	hypersensitivity	NOUN
dpc-2229	30	37	and	and	CCONJ
dpc-2229	30	38	alcohol	alcohol	NOUN
dpc-2229	30	39	-	-	PUNCT
dpc-2229	30	40	induced	induce	VERB
dpc-2229	30	41	facial	facial	NOUN
dpc-2229	30	42	flushing	flush	VERB
dpc-2229	30	43	[	[	PUNCT
dpc-2229	30	44	2	2	NUM
dpc-2229	30	45	-	-	SYM
dpc-2229	30	46	4	4	NUM
dpc-2229	30	47	]	]	PUNCT
dpc-2229	30	48	.	.	PUNCT
dpc-2229	31	1	2	2	NUM
dpc-2229	31	2	research	research	NOUN
dpc-2229	31	3	letter	letter	NOUN
dpc-2229	31	4	|	|	ADV
dpc-2229	31	5	dermatol	dermatol	ADJ
dpc-2229	31	6	pract	pract	NOUN
dpc-2229	31	7	concept	concept	NOUN
dpc-2229	31	8	.	.	PUNCT
dpc-2229	32	1	2022;12(4):e2022184	2022;12(4):e2022184	NUM
dpc-2229	32	2	figure	figure	NOUN
dpc-2229	32	3	1	1	NUM
dpc-2229	32	4	.	.	PUNCT
dpc-2229	32	5	dupilumab	dupilumab	NOUN
dpc-2229	32	6	-	-	PUNCT
dpc-2229	32	7	associated	associate	VERB
dpc-2229	32	8	facial	facial	ADJ
dpc-2229	32	9	erythema	erythema	NOUN
dpc-2229	32	10	.	.	PUNCT
dpc-2229	33	1	(	(	PUNCT
dpc-2229	33	2	a	a	X
dpc-2229	33	3	)	)	PUNCT
dpc-2229	33	4	new	new	ADJ
dpc-2229	33	5	onset	onset	NOUN
dpc-2229	33	6	of	of	ADP
dpc-2229	33	7	scaly	scaly	NOUN
dpc-2229	33	8	erythematous	erythematous	ADJ
dpc-2229	33	9	plaques	plaque	NOUN
dpc-2229	33	10	on	on	ADP
dpc-2229	33	11	the	the	DET
dpc-2229	33	12	forehead	forehead	NOUN
dpc-2229	33	13	and	and	CCONJ
dpc-2229	33	14	cheeks	cheek	NOUN
dpc-2229	33	15	,	,	PUNCT
dpc-2229	33	16	without	without	ADP
dpc-2229	33	17	affecting	affect	VERB
dpc-2229	33	18	nasolabial	nasolabial	ADJ
dpc-2229	33	19	folds	fold	NOUN
dpc-2229	33	20	or	or	CCONJ
dpc-2229	33	21	the	the	DET
dpc-2229	33	22	palpebral	palpebral	ADJ
dpc-2229	33	23	region	region	NOUN
dpc-2229	33	24	,	,	PUNCT
dpc-2229	33	25	6	6	NUM
dpc-2229	33	26	weeks	week	NOUN
dpc-2229	33	27	after	after	ADP
dpc-2229	33	28	initiating	initiate	VERB
dpc-2229	33	29	dupilumab	dupilumab	NOUN
dpc-2229	33	30	therapy	therapy	NOUN
dpc-2229	33	31	.	.	PUNCT
dpc-2229	34	1	(	(	PUNCT
dpc-2229	34	2	b	b	X
dpc-2229	34	3	)	)	PUNCT
dpc-2229	34	4	dermoscopy	dermoscopy	NOUN
dpc-2229	34	5	examination	examination	NOUN
dpc-2229	34	6	shows	show	VERB
dpc-2229	34	7	white	white	ADJ
dpc-2229	34	8	scaling	scaling	NOUN
dpc-2229	34	9	and	and	CCONJ
dpc-2229	34	10	a	a	DET
dpc-2229	34	11	central	central	ADJ
dpc-2229	34	12	pustule	pustule	NOUN
dpc-2229	34	13	.	.	PUNCT
dpc-2229	35	1	figure	figure	NOUN
dpc-2229	35	2	2	2	NUM
dpc-2229	35	3	.	.	PUNCT
dpc-2229	35	4	almost	almost	ADV
dpc-2229	35	5	complete	complete	ADJ
dpc-2229	35	6	resolution	resolution	NOUN
dpc-2229	35	7	after	after	ADP
dpc-2229	35	8	a	a	DET
dpc-2229	35	9	single	single	ADJ
dpc-2229	35	10	dose	dose	NOUN
dpc-2229	35	11	of	of	ADP
dpc-2229	35	12	oral	oral	ADJ
dpc-2229	35	13	ivermectin	ivermectin	NOUN
dpc-2229	35	14	(	(	PUNCT
dpc-2229	35	15	200	200	NUM
dpc-2229	35	16	mcg	mcg	PROPN
dpc-2229	35	17	/	/	SYM
dpc-2229	35	18	kg	kg	PROPN
dpc-2229	35	19	)	)	PUNCT
dpc-2229	35	20	.	.	PUNCT
dpc-2229	36	1	in	in	ADP
dpc-2229	36	2	 	 	SPACE
dpc-2229	36	3	a	a	DET
dpc-2229	36	4	 	 	SPACE
dpc-2229	36	5	retrospective	retrospective	ADJ
dpc-2229	36	6	study	study	NOUN
dpc-2229	36	7	of	of	ADP
dpc-2229	36	8	94	94	NUM
dpc-2229	36	9	patients	patient	NOUN
dpc-2229	36	10	with	with	ADP
dpc-2229	36	11	dupilumab	dupilumab	NOUN
dpc-2229	36	12	[	[	X
dpc-2229	36	13	4	4	NUM
dpc-2229	36	14	]	]	PUNCT
dpc-2229	36	15	,	,	PUNCT
dpc-2229	36	16	6	6	NUM
dpc-2229	36	17	%	%	NOUN
dpc-2229	36	18	presented	present	VERB
dpc-2229	36	19	rosacea	rosacea	NOUN
dpc-2229	36	20	-	-	PUNCT
dpc-2229	36	21	like	like	ADJ
dpc-2229	36	22	folliculitis	folliculitis	NOUN
dpc-2229	36	23	and	and	CCONJ
dpc-2229	36	24	increased	increase	VERB
dpc-2229	36	25	demodex	demodex	NOUN
dpc-2229	36	26	count	count	NOUN
dpc-2229	36	27	in	in	ADP
dpc-2229	36	28	reflectance	reflectance	NOUN
dpc-2229	36	29	confocal	confocal	ADJ
dpc-2229	36	30	microscopy	microscopy	NOUN
dpc-2229	36	31	[	[	X
dpc-2229	36	32	1,4	1,4	NUM
dpc-2229	36	33	]	]	PUNCT
dpc-2229	36	34	.	.	PUNCT
dpc-2229	37	1	although	although	SCONJ
dpc-2229	37	2	dfe	dfe	PROPN
dpc-2229	37	3	pathogenesis	pathogenesis	NOUN
dpc-2229	37	4	remains	remain	VERB
dpc-2229	37	5	unclear	unclear	ADJ
dpc-2229	37	6	,	,	PUNCT
dpc-2229	37	7	recent	recent	ADJ
dpc-2229	37	8	studies	study	NOUN
dpc-2229	37	9	have	have	AUX
dpc-2229	37	10	hypothesized	hypothesize	VERB
dpc-2229	37	11	that	that	SCONJ
dpc-2229	37	12	il-4	il-4	NOUN
dpc-2229	37	13	blockage	blockage	NOUN
dpc-2229	37	14	shifts	shift	NOUN
dpc-2229	37	15	th1/	th1/	X
dpc-2229	37	16	th2	th2	PROPN
dpc-2229	37	17	balance	balance	NOUN
dpc-2229	37	18	towards	towards	ADP
dpc-2229	37	19	th1	th1	PROPN
dpc-2229	37	20	/	/	SYM
dpc-2229	37	21	th17	th17	PROPN
dpc-2229	37	22	-	-	PUNCT
dpc-2229	37	23	mediated	mediate	VERB
dpc-2229	37	24	dermatoses	dermatosis	NOUN
dpc-2229	37	25	[	[	X
dpc-2229	37	26	2	2	NUM
dpc-2229	37	27	]	]	PUNCT
dpc-2229	37	28	.	.	PUNCT
dpc-2229	38	1	in	in	ADP
dpc-2229	38	2	rosacea	rosacea	NOUN
dpc-2229	38	3	,	,	PUNCT
dpc-2229	38	4	especially	especially	ADV
dpc-2229	38	5	if	if	SCONJ
dpc-2229	38	6	papulopustular	papulopustular	ADJ
dpc-2229	38	7	,	,	PUNCT
dpc-2229	38	8	the	the	DET
dpc-2229	38	9	main	main	ADJ
dpc-2229	38	10	factors	factor	NOUN
dpc-2229	38	11	are	be	AUX
dpc-2229	38	12	induction	induction	NOUN
dpc-2229	38	13	of	of	ADP
dpc-2229	38	14	demodex	demodex	NOUN
dpc-2229	38	15	proliferation	proliferation	NOUN
dpc-2229	38	16	by	by	ADP
dpc-2229	38	17	th2	th2	PROPN
dpc-2229	38	18	blockade	blockade	NOUN
dpc-2229	38	19	and	and	CCONJ
dpc-2229	38	20	th17	th17	NOUN
dpc-2229	38	21	-	-	PUNCT
dpc-2229	38	22	infllamatory	infllamatory	ADJ
dpc-2229	38	23	response	response	NOUN
dpc-2229	38	24	[	[	X
dpc-2229	38	25	1	1	NUM
dpc-2229	38	26	]	]	PUNCT
dpc-2229	38	27	.	.	PUNCT
dpc-2229	39	1	regarding	regard	VERB
dpc-2229	39	2	dfe	dfe	PROPN
dpc-2229	39	3	treatment	treatment	NOUN
dpc-2229	39	4	,	,	PUNCT
dpc-2229	39	5	topical	topical	ADJ
dpc-2229	39	6	corticosteroids	corticosteroid	NOUN
dpc-2229	39	7	and	and	CCONJ
dpc-2229	39	8	calcineurin	calcineurin	ADJ
dpc-2229	39	9	inhibitors	inhibitor	NOUN
dpc-2229	39	10	are	be	AUX
dpc-2229	39	11	the	the	DET
dpc-2229	39	12	most	most	ADV
dpc-2229	39	13	used	use	VERB
dpc-2229	39	14	,	,	PUNCT
dpc-2229	39	15	although	although	SCONJ
dpc-2229	39	16	with	with	ADP
dpc-2229	39	17	low	low	ADJ
dpc-2229	39	18	response	response	NOUN
dpc-2229	39	19	rates	rate	NOUN
dpc-2229	39	20	.	.	PUNCT
dpc-2229	40	1	however	however	ADV
dpc-2229	40	2	,	,	PUNCT
dpc-2229	40	3	management	management	NOUN
dpc-2229	40	4	of	of	ADP
dpc-2229	40	5	dfe	dfe	PROPN
dpc-2229	40	6	should	should	AUX
dpc-2229	40	7	start	start	VERB
dpc-2229	40	8	with	with	ADP
dpc-2229	40	9	a	a	DET
dpc-2229	40	10	precise	precise	ADJ
dpc-2229	40	11	differential	differential	ADJ
dpc-2229	40	12	diagnosis	diagnosis	NOUN
dpc-2229	40	13	,	,	PUNCT
dpc-2229	40	14	since	since	SCONJ
dpc-2229	40	15	acd	acd	NOUN
dpc-2229	40	16	,	,	PUNCT
dpc-2229	40	17	rosacea	rosacea	NOUN
dpc-2229	40	18	,	,	PUNCT
dpc-2229	40	19	tcw	tcw	NOUN
dpc-2229	40	20	and	and	CCONJ
dpc-2229	40	21	mf	mf	NOUN
dpc-2229	40	22	-	-	ADJ
dpc-2229	40	23	dermatitis	dermatitis	NOUN
dpc-2229	40	24	respond	respond	VERB
dpc-2229	40	25	to	to	ADP
dpc-2229	40	26	different	different	ADJ
dpc-2229	40	27	approaches	approach	NOUN
dpc-2229	40	28	[	[	X
dpc-2229	40	29	2	2	NUM
dpc-2229	40	30	,	,	PUNCT
dpc-2229	40	31	 	 	SPACE
dpc-2229	40	32	5	5	NUM
dpc-2229	40	33	]	]	PUNCT
dpc-2229	40	34	.	.	PUNCT
dpc-2229	41	1	thus	thus	ADV
dpc-2229	41	2	,	,	PUNCT
dpc-2229	41	3	most	most	ADJ
dpc-2229	41	4	treatment	treatment	NOUN
dpc-2229	41	5	failures	failure	NOUN
dpc-2229	41	6	could	could	AUX
dpc-2229	41	7	be	be	AUX
dpc-2229	41	8	explained	explain	VERB
dpc-2229	41	9	by	by	ADP
dpc-2229	41	10	dfe	dfe	PROPN
dpc-2229	41	11	being	be	AUX
dpc-2229	41	12	erroneously	erroneously	ADV
dpc-2229	41	13	thought	think	VERB
dpc-2229	41	14	of	of	ADP
dpc-2229	41	15	as	as	ADP
dpc-2229	41	16	a	a	DET
dpc-2229	41	17	unique	unique	ADJ
dpc-2229	41	18	entity	entity	NOUN
dpc-2229	41	19	.	.	PUNCT
dpc-2229	42	1	evidence	evidence	NOUN
dpc-2229	42	2	on	on	ADP
dpc-2229	42	3	rosacea	rosacea	NOUN
dpc-2229	42	4	-	-	PUNCT
dpc-2229	42	5	like	like	ADJ
dpc-2229	42	6	dermatitis	dermatitis	NOUN
dpc-2229	42	7	treatment	treatment	NOUN
dpc-2229	42	8	remains	remain	VERB
dpc-2229	42	9	sparse	sparse	ADJ
dpc-2229	42	10	[	[	PUNCT
dpc-2229	42	11	2	2	NUM
dpc-2229	42	12	]	]	PUNCT
dpc-2229	42	13	.	.	PUNCT
dpc-2229	43	1	partial	partial	ADJ
dpc-2229	43	2	or	or	CCONJ
dpc-2229	43	3	complete	complete	ADJ
dpc-2229	43	4	response	response	NOUN
dpc-2229	43	5	to	to	ADP
dpc-2229	43	6	acaricidal	acaricidal	NOUN
dpc-2229	43	7	agents	agent	NOUN
dpc-2229	43	8	such	such	ADJ
dpc-2229	43	9	as	as	ADP
dpc-2229	43	10	topical	topical	ADJ
dpc-2229	43	11	and	and	CCONJ
dpc-2229	43	12	oral	oral	ADJ
dpc-2229	43	13	metronidazole	metronidazole	NOUN
dpc-2229	43	14	,	,	PUNCT
dpc-2229	43	15	topical	topical	ADJ
dpc-2229	43	16	ivermectin	ivermectin	NOUN
dpc-2229	43	17	or	or	CCONJ
dpc-2229	43	18	doxycycline	doxycycline	NOUN
dpc-2229	43	19	have	have	AUX
dpc-2229	43	20	been	be	AUX
dpc-2229	43	21	reported	report	VERB
dpc-2229	43	22	[	[	PUNCT
dpc-2229	43	23	2	2	NUM
dpc-2229	43	24	]	]	PUNCT
dpc-2229	43	25	.	.	PUNCT
dpc-2229	44	1	topical	topical	ADJ
dpc-2229	44	2	ivermectin	ivermectin	NOUN
dpc-2229	44	3	is	be	AUX
dpc-2229	44	4	a	a	DET
dpc-2229	44	5	firstline	firstline	NOUN
dpc-2229	44	6	therapy	therapy	NOUN
dpc-2229	44	7	for	for	ADP
dpc-2229	44	8	papulopustular	papulopustular	ADJ
dpc-2229	44	9	rosacea	rosacea	NOUN
dpc-2229	44	10	,	,	PUNCT
dpc-2229	44	11	although	although	SCONJ
dpc-2229	44	12	it	it	PRON
dpc-2229	44	13	requires	require	VERB
dpc-2229	44	14	prolonged	prolonged	ADJ
dpc-2229	44	15	treatment	treatment	NOUN
dpc-2229	44	16	(	(	PUNCT
dpc-2229	44	17	up	up	ADP
dpc-2229	44	18	to	to	PART
dpc-2229	44	19	12	12	NUM
dpc-2229	44	20	weeks	week	NOUN
dpc-2229	44	21	)	)	PUNCT
dpc-2229	44	22	.	.	PUNCT
dpc-2229	45	1	oral	oral	ADJ
dpc-2229	45	2	ivermectin	ivermectin	NOUN
dpc-2229	45	3	treatment	treatment	NOUN
dpc-2229	45	4	for	for	ADP
dpc-2229	45	5	rosacea	rosacea	NOUN
dpc-2229	45	6	has	have	AUX
dpc-2229	45	7	been	be	AUX
dpc-2229	45	8	reported	report	VERB
dpc-2229	45	9	in	in	ADP
dpc-2229	45	10	isolated	isolated	ADJ
dpc-2229	45	11	cases	case	NOUN
dpc-2229	45	12	with	with	ADP
dpc-2229	45	13	satisfactory	satisfactory	ADJ
dpc-2229	45	14	results	result	NOUN
dpc-2229	45	15	.	.	PUNCT
dpc-2229	46	1	it	it	PRON
dpc-2229	46	2	has	have	VERB
dpc-2229	46	3	very	very	ADV
dpc-2229	46	4	low	low	ADJ
dpc-2229	46	5	systemic	systemic	ADJ
dpc-2229	46	6	ae	ae	PROPN
dpc-2229	46	7	(	(	PUNCT
dpc-2229	46	8	<	<	X
dpc-2229	46	9	1	1	NUM
dpc-2229	46	10	%	%	NOUN
dpc-2229	46	11	)	)	PUNCT
dpc-2229	46	12	and	and	CCONJ
dpc-2229	46	13	two	two	NUM
dpc-2229	46	14	main	main	ADJ
dpc-2229	46	15	advantages	advantage	NOUN
dpc-2229	46	16	:	:	PUNCT
dpc-2229	46	17	single	single	ADJ
dpc-2229	46	18	administration	administration	NOUN
dpc-2229	46	19	schedule	schedule	NOUN
dpc-2229	46	20	and	and	CCONJ
dpc-2229	46	21	avoidance	avoidance	NOUN
dpc-2229	46	22	of	of	ADP
dpc-2229	46	23	local	local	ADJ
dpc-2229	46	24	ae	ae	PROPN
dpc-2229	46	25	.	.	PUNCT
dpc-2229	47	1	in	in	ADP
dpc-2229	47	2	patients	patient	NOUN
dpc-2229	47	3	under	under	ADP
dpc-2229	47	4	treatment	treatment	NOUN
dpc-2229	47	5	with	with	ADP
dpc-2229	47	6	dupilumab	dupilumab	NOUN
dpc-2229	47	7	presenting	present	VERB
dpc-2229	47	8	with	with	ADP
dpc-2229	47	9	facial	facial	ADJ
dpc-2229	47	10	erythema	erythema	NOUN
dpc-2229	47	11	,	,	PUNCT
dpc-2229	47	12	dfe	dfe	PROPN
dpc-2229	47	13	should	should	AUX
dpc-2229	47	14	be	be	AUX
dpc-2229	47	15	considered	consider	VERB
dpc-2229	47	16	.	.	PUNCT
dpc-2229	48	1	rather	rather	ADV
dpc-2229	48	2	than	than	ADP
dpc-2229	48	3	a	a	DET
dpc-2229	48	4	unique	unique	ADJ
dpc-2229	48	5	entity	entity	NOUN
dpc-2229	48	6	,	,	PUNCT
dpc-2229	48	7	dfe	dfe	PROPN
dpc-2229	48	8	should	should	AUX
dpc-2229	48	9	be	be	AUX
dpc-2229	48	10	considered	consider	VERB
dpc-2229	48	11	as	as	ADP
dpc-2229	48	12	a	a	DET
dpc-2229	48	13	compendium	compendium	NOUN
dpc-2229	48	14	of	of	ADP
dpc-2229	48	15	differential	differential	NOUN
dpc-2229	48	16	diagnoses	diagnosis	NOUN
dpc-2229	48	17	.	.	PUNCT
dpc-2229	49	1	if	if	SCONJ
dpc-2229	49	2	rosacea	rosacea	NOUN
dpc-2229	49	3	-	-	PUNCT
dpc-2229	49	4	like	like	ADJ
dpc-2229	49	5	dermatitis	dermatitis	NOUN
dpc-2229	49	6	is	be	AUX
dpc-2229	49	7	suspected	suspect	VERB
dpc-2229	49	8	,	,	PUNCT
dpc-2229	49	9	oral	oral	ADJ
dpc-2229	49	10	ivermectin	ivermectin	NOUN
dpc-2229	49	11	could	could	AUX
dpc-2229	49	12	represent	represent	VERB
dpc-2229	49	13	a	a	DET
dpc-2229	49	14	good	good	ADJ
dpc-2229	49	15	and	and	CCONJ
dpc-2229	49	16	well	well	ADV
dpc-2229	49	17	-	-	PUNCT
dpc-2229	49	18	tolerated	tolerate	VERB
dpc-2229	49	19	alternative	alternative	NOUN
dpc-2229	49	20	.	.	PUNCT
dpc-2229	50	1	references	reference	NOUN
dpc-2229	50	2	1	1	NUM
dpc-2229	50	3	.	.	PUNCT
dpc-2229	51	1	zhu	zhu	PROPN
dpc-2229	51	2	ga	ga	PROPN
dpc-2229	51	3	,	,	PUNCT
dpc-2229	51	4	chen	chen	PROPN
dpc-2229	51	5	jk	jk	PROPN
dpc-2229	51	6	,	,	PUNCT
dpc-2229	51	7	chiou	chiou	VERB
dpc-2229	51	8	a	a	PRON
dpc-2229	51	9	,	,	PUNCT
dpc-2229	51	10	ko	ko	PROPN
dpc-2229	51	11	j	j	PROPN
dpc-2229	51	12	,	,	PUNCT
dpc-2229	51	13	honari	honari	PROPN
dpc-2229	51	14	g.	g.	PROPN
dpc-2229	51	15	assessment	assessment	NOUN
dpc-2229	51	16	of	of	ADP
dpc-2229	51	17	the	the	DET
dpc-2229	51	18	development	development	NOUN
dpc-2229	51	19	of	of	ADP
dpc-2229	51	20	new	new	ADJ
dpc-2229	51	21	regional	regional	ADJ
dpc-2229	51	22	dermatoses	dermatosis	NOUN
dpc-2229	51	23	in	in	ADP
dpc-2229	51	24	patients	patient	NOUN
dpc-2229	51	25	treated	treat	VERB
dpc-2229	51	26	for	for	ADP
dpc-2229	51	27	atopic	atopic	NOUN
dpc-2229	51	28	dermatitis	dermatitis	NOUN
dpc-2229	51	29	with	with	ADP
dpc-2229	51	30	dupilumab	dupilumab	NOUN
dpc-2229	51	31	.	.	PUNCT
dpc-2229	52	1	jama	jama	PROPN
dpc-2229	52	2	dermatol	dermatol	NOUN
dpc-2229	52	3	.	.	PUNCT
dpc-2229	53	1	2019;155(7):850	2019;155(7):850	NUM
dpc-2229	53	2	-	-	SYM
dpc-2229	53	3	852	852	NUM
dpc-2229	53	4	.	.	PUNCT
dpc-2229	54	1	doi	doi	NOUN
dpc-2229	54	2	:	:	PUNCT
dpc-2229	54	3	10.1001	10.1001	NUM
dpc-2229	54	4	/	/	SYM
dpc-2229	54	5	jamadermatol.2019.0109	jamadermatol.2019.0109	ADJ
dpc-2229	54	6	.	.	PUNCT
dpc-2229	55	1	pmid	pmid	NOUN
dpc-2229	55	2	:	:	PUNCT
dpc-2229	55	3	31042259	31042259	NUM
dpc-2229	55	4	.	.	PUNCT
dpc-2229	56	1	pmcid	pmcid	NOUN
dpc-2229	56	2	:	:	PUNCT
dpc-2229	56	3	pmc6495362	pmc6495362	PROPN
dpc-2229	56	4	.	.	PUNCT
dpc-2229	57	1	2	2	X
dpc-2229	57	2	.	.	X
dpc-2229	57	3	jaros	jaros	PROPN
dpc-2229	57	4	j	j	PROPN
dpc-2229	57	5	,	,	PUNCT
dpc-2229	57	6	hendricks	hendricks	PROPN
dpc-2229	57	7	aj	aj	PROPN
dpc-2229	57	8	,	,	PUNCT
dpc-2229	57	9	shi	shi	PROPN
dpc-2229	57	10	vy	vy	PROPN
dpc-2229	57	11	,	,	PUNCT
dpc-2229	57	12	lio	lio	PROPN
dpc-2229	57	13	pa	pa	PROPN
dpc-2229	57	14	.	.	PROPN
dpc-2229	58	1	a	a	DET
dpc-2229	58	2	practical	practical	ADJ
dpc-2229	58	3	approach	approach	NOUN
dpc-2229	58	4	to	to	ADP
dpc-2229	58	5	recalcitrant	recalcitrant	ADJ
dpc-2229	58	6	face	face	NOUN
dpc-2229	58	7	and	and	CCONJ
dpc-2229	58	8	neck	neck	NOUN
dpc-2229	58	9	dermatitis	dermatitis	NOUN
dpc-2229	58	10	in	in	ADP
dpc-2229	58	11	atopic	atopic	NOUN
dpc-2229	58	12	dermatitis	dermatitis	NOUN
dpc-2229	58	13	.	.	PUNCT
dpc-2229	59	1	dermat	dermat	PROPN
dpc-2229	59	2	contact	contact	PROPN
dpc-2229	59	3	atopic	atopic	NOUN
dpc-2229	59	4	occup	occup	ADJ
dpc-2229	59	5	drug	drug	NOUN
dpc-2229	59	6	.	.	PUNCT
dpc-2229	60	1	2020;31(3):169–717	2020;31(3):169–717	X
dpc-2229	60	2	.	.	PUNCT
dpc-2229	61	1	doi	doi	NOUN
dpc-2229	61	2	:	:	PUNCT
dpc-2229	61	3	10.1097	10.1097	NUM
dpc-2229	61	4	/	/	SYM
dpc-2229	61	5	der.0000000000000590	der.0000000000000590	NUM
dpc-2229	61	6	.	.	PUNCT
dpc-2229	62	1	pmid	pmid	NOUN
dpc-2229	62	2	:	:	PUNCT
dpc-2229	62	3	32355092	32355092	NUM
dpc-2229	62	4	.	.	PUNCT
dpc-2229	63	1	3	3	X
dpc-2229	63	2	.	.	X
dpc-2229	63	3	jo	jo	PROPN
dpc-2229	63	4	ce	ce	PROPN
dpc-2229	63	5	,	,	PUNCT
dpc-2229	63	6	finstad	finstad	PROPN
dpc-2229	63	7	a	a	PRON
dpc-2229	63	8	,	,	PUNCT
dpc-2229	63	9	georgakopoulos	georgakopoulos	PROPN
dpc-2229	63	10	jr	jr	PROPN
dpc-2229	63	11	,	,	PUNCT
dpc-2229	63	12	piguet	piguet	PROPN
dpc-2229	63	13	v	v	PROPN
dpc-2229	63	14	,	,	PUNCT
dpc-2229	63	15	yeung	yeung	PROPN
dpc-2229	63	16	j	j	PROPN
dpc-2229	63	17	,	,	PUNCT
dpc-2229	63	18	drucker	drucker	PROPN
dpc-2229	63	19	am	be	AUX
dpc-2229	63	20	.	.	PUNCT
dpc-2229	64	1	facial	facial	ADJ
dpc-2229	64	2	and	and	CCONJ
dpc-2229	64	3	neck	neck	NOUN
dpc-2229	64	4	erythema	erythema	NOUN
dpc-2229	64	5	associated	associate	VERB
dpc-2229	64	6	with	with	ADP
dpc-2229	64	7	research	research	NOUN
dpc-2229	64	8	letter	letter	NOUN
dpc-2229	65	1	|	|	ADV
dpc-2229	65	2	dermatol	dermatol	ADJ
dpc-2229	65	3	pract	pract	NOUN
dpc-2229	65	4	concept	concept	NOUN
dpc-2229	65	5	.	.	PUNCT
dpc-2229	66	1	2022;12(4):e2022184	2022;12(4):e2022184	NUM
dpc-2229	66	2	3	3	NUM
dpc-2229	66	3	dupilumab	dupilumab	NOUN
dpc-2229	66	4	treatment	treatment	NOUN
dpc-2229	66	5	:	:	PUNCT
dpc-2229	66	6	a	a	DET
dpc-2229	66	7	systematic	systematic	ADJ
dpc-2229	66	8	review	review	NOUN
dpc-2229	66	9	.	.	PUNCT
dpc-2229	67	1	j	j	PROPN
dpc-2229	67	2	am	be	AUX
dpc-2229	67	3	acad	acad	ADJ
dpc-2229	67	4	dermatol	dermatol	NOUN
dpc-2229	67	5	.	.	PUNCT
dpc-2229	68	1	2021;84(5):1339	2021;84(5):1339	PROPN
dpc-2229	68	2	-	-	SYM
dpc-2229	68	3	1347	1347	NUM
dpc-2229	68	4	.	.	PUNCT
dpc-2229	69	1	doi	doi	NOUN
dpc-2229	69	2	:	:	PUNCT
dpc-2229	69	3	10.1016	10.1016	NUM
dpc-2229	69	4	/	/	SYM
dpc-2229	69	5	j.jaad.2021.01.012	j.jaad.2021.01.012	PROPN
dpc-2229	69	6	.	.	PUNCT
dpc-2229	70	1	pmid	pmid	NOUN
dpc-2229	70	2	:	:	PUNCT
dpc-2229	70	3	33428978	33428978	NUM
dpc-2229	70	4	.	.	PUNCT
dpc-2229	71	1	4	4	X
dpc-2229	71	2	.	.	X
dpc-2229	71	3	okiyama	okiyama	PROPN
dpc-2229	71	4	n	n	CCONJ
dpc-2229	71	5	,	,	PUNCT
dpc-2229	71	6	nakamura	nakamura	PROPN
dpc-2229	71	7	y	y	PROPN
dpc-2229	71	8	,	,	PUNCT
dpc-2229	71	9	ishitsuka	ishitsuka	PROPN
dpc-2229	71	10	y	y	PROPN
dpc-2229	71	11	,	,	PUNCT
dpc-2229	71	12	et	et	PROPN
dpc-2229	71	13	al	al	PROPN
dpc-2229	71	14	.	.	PUNCT
dpc-2229	72	1	successful	successful	ADJ
dpc-2229	72	2	topical	topical	ADJ
dpc-2229	72	3	treatment	treatment	NOUN
dpc-2229	72	4	with	with	ADP
dpc-2229	72	5	ketoconazole	ketoconazole	NOUN
dpc-2229	72	6	for	for	ADP
dpc-2229	72	7	facial	facial	ADJ
dpc-2229	72	8	rashes	rash	NOUN
dpc-2229	72	9	refractory	refractory	NOUN
dpc-2229	72	10	to	to	PART
dpc-2229	72	11	dupilumab	dupilumab	VERB
dpc-2229	72	12	in	in	ADP
dpc-2229	72	13	patients	patient	NOUN
dpc-2229	72	14	with	with	ADP
dpc-2229	72	15	atopic	atopic	NOUN
dpc-2229	72	16	dermatitis	dermatitis	NOUN
dpc-2229	72	17	:	:	PUNCT
dpc-2229	72	18	case	case	NOUN
dpc-2229	72	19	reports	report	VERB
dpc-2229	72	20	.	.	PUNCT
dpc-2229	73	1	j	j	PROPN
dpc-2229	73	2	eur	eur	PROPN
dpc-2229	73	3	acad	acad	PROPN
dpc-2229	73	4	dermatol	dermatol	NOUN
dpc-2229	73	5	venereol	venereol	NOUN
dpc-2229	73	6	.	.	PUNCT
dpc-2229	74	1	2020;34(9):e474	2020;34(9):e474	ADJ
dpc-2229	74	2	-	-	PUNCT
dpc-2229	74	3	e476	e476	PROPN
dpc-2229	74	4	.	.	PUNCT
dpc-2229	74	5	doi	doi	PROPN
dpc-2229	74	6	:	:	PUNCT
dpc-2229	74	7	10.1111/	10.1111/	NUM
dpc-2229	74	8	jdv.16383	jdv.16383	PROPN
dpc-2229	74	9	.	.	PUNCT
dpc-2229	75	1	pmid	pmid	NOUN
dpc-2229	75	2	:	:	PUNCT
dpc-2229	75	3	32215964	32215964	NUM
dpc-2229	75	4	.	.	PUNCT
dpc-2229	76	1	5	5	X
dpc-2229	76	2	.	.	X
dpc-2229	76	3	gao	gao	PROPN
dpc-2229	76	4	dx	dx	PROPN
dpc-2229	76	5	,	,	PUNCT
dpc-2229	76	6	song	song	PROPN
dpc-2229	76	7	s	s	PROPN
dpc-2229	76	8	,	,	PUNCT
dpc-2229	76	9	kahn	kahn	PROPN
dpc-2229	76	10	js	js	PROPN
dpc-2229	76	11	,	,	PUNCT
dpc-2229	76	12	et	et	PROPN
dpc-2229	76	13	al	al	PROPN
dpc-2229	76	14	.	.	PUNCT
dpc-2229	77	1	treatment	treatment	NOUN
dpc-2229	77	2	of	of	ADP
dpc-2229	77	3	patients	patient	NOUN
dpc-2229	77	4	experiencing	experience	VERB
dpc-2229	77	5	dupilumab	dupilumab	NOUN
dpc-2229	77	6	facial	facial	ADJ
dpc-2229	77	7	redness	redness	NOUN
dpc-2229	77	8	with	with	ADP
dpc-2229	77	9	itraconazole	itraconazole	NOUN
dpc-2229	77	10	and	and	CCONJ
dpc-2229	77	11	fluconazole	fluconazole	NOUN
dpc-2229	77	12	:	:	PUNCT
dpc-2229	77	13	a	a	DET
dpc-2229	77	14	single	single	ADJ
dpc-2229	77	15	-	-	PUNCT
dpc-2229	77	16	institutional	institutional	ADJ
dpc-2229	77	17	,	,	PUNCT
dpc-2229	77	18	retrospective	retrospective	ADJ
dpc-2229	77	19	medical	medical	ADJ
dpc-2229	77	20	record	record	NOUN
dpc-2229	77	21	review	review	NOUN
dpc-2229	77	22	.	.	PUNCT
dpc-2229	78	1	j	j	NOUN
dpc-2229	78	2	  	  	SPACE
dpc-2229	78	3	am	be	AUX
dpc-2229	78	4	acad	acad	ADJ
dpc-2229	78	5	dermatol	dermatol	NOUN
dpc-2229	78	6	.	.	PUNCT
dpc-2229	79	1	2022;86(4):938	2022;86(4):938	NUM
dpc-2229	79	2	-	-	PUNCT
dpc-2229	79	3	940	940	NUM
dpc-2229	79	4	.	.	PUNCT
dpc-2229	80	1	doi	doi	NOUN
dpc-2229	80	2	:	:	PUNCT
dpc-2229	80	3	10.1016	10.1016	NUM
dpc-2229	80	4	/	/	SYM
dpc-2229	80	5	j.	j.	PROPN
dpc-2229	80	6	jaad.2021.03.070	jaad.2021.03.070	PROPN
dpc-2229	80	7	.	.	PUNCT
dpc-2229	81	1	pmid	pmid	NOUN
dpc-2229	81	2	:	:	PUNCT
dpc-2229	81	3	33775718	33775718	NUM
dpc-2229	81	4	.	.	PUNCT